Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community ca

@article{Witzig2017LongtermFO,
  title={Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community ca},
  author={Thomas E Witzig and Patrick B. Johnston and Betsy R Laplant and Paul J. Kurtin and Levi D Pederson and Dennis F. Moore and Nassim H. Nabbout and Daniel A. Nikcevich and Kendrith Martin Rowland and Axel M Grothey},
  journal={American journal of hematology},
  year={2017},
  volume={92 10},
  pages={
          1004-1010
        }
}
Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinum-based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD was delivered q21 days and consisted of rituximab 375 mg/m2 IV weekly x 4 doses (cycle 1 only… CONTINUE READING
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Genetic polymorphisms of SCN 9 A are associated with oxaliplatin - induced neuropa

M Sereno, G Gutierrez-Gutierrez, JM Rubio
  • BMC Cancer
  • 2017

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
VIEW 1 EXCERPT